Artelo biosciences to present novel scientific insights for art26.12 at the 4th ace drug discovery summit on april 3, 2025

Solana beach, calif., march 31, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that myles osborn, lead medicinal chemist at artelo biosciences, will be presenting at 12:30pm bst on april 3, 2025 during the 4th ace drug discovery summit being held at the insurance hall, london, uk.
ARTL Ratings Summary
ARTL Quant Ranking